These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17673715)

  • 1. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke.
    Kunte H; Schmidt S; Eliasziw M; del Zoppo GJ; Simard JM; Masuhr F; Weih M; Dirnagl U
    Stroke; 2007 Sep; 38(9):2526-30. PubMed ID: 17673715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas.
    Kunte H; Busch MA; Trostdorf K; Vollnberg B; Harms L; Mehta RI; Castellani RJ; Mandava P; Kent TA; Simard JM
    Ann Neurol; 2012 Nov; 72(5):799-806. PubMed ID: 23280795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-selective cation channels, transient receptor potential channels and ischemic stroke.
    Simard JM; Tarasov KV; Gerzanich V
    Biochim Biophys Acta; 2007 Aug; 1772(8):947-57. PubMed ID: 17446049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke.
    Simard JM; Yurovsky V; Tsymbalyuk N; Melnichenko L; Ivanova S; Gerzanich V
    Stroke; 2009 Feb; 40(2):604-9. PubMed ID: 19023097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of sulfonylureas on patients with type 2 diabetes and acute nonlacunar ischemic stroke].
    Chen DM; Yu YR
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Sep; 45(5):810-3. PubMed ID: 25341346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sulfonylurea drugs for type 2 diabetes].
    Toyota T
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():339-45. PubMed ID: 12387015
    [No Abstract]   [Full Text] [Related]  

  • 7. [Polymorphism of the sulfonylurea receptor gene in type 2 diabetes mellitus].
    Owecki M; Horst-Sikorska W; Kaczmarek M; Słomski R; Sowiński J
    Pol Arch Med Wewn; 2003 Feb; 109(2):143-8. PubMed ID: 12879777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes.
    Weih M; Amberger N; Wegener S; Dirnagl U; Reuter T; Einhäupl K
    Stroke; 2001 Sep; 32(9):2029-32. PubMed ID: 11546892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke.
    Simard JM; Chen M; Tarasov KV; Bhatta S; Ivanova S; Melnitchenko L; Tsymbalyuk N; West GA; Gerzanich V
    Nat Med; 2006 Apr; 12(4):433-40. PubMed ID: 16550187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfonylurea receptor gene 16-3 polymorphism - association with sulfonylurea or insulin treatment in type 2 diabetic subjects.
    Zychma MJ; Gumprecht J; Strojek K; Grzeszczak W; Moczulski D; Trautsolt W; Karasek D
    Med Sci Monit; 2002 Jul; 8(7):CR512-5. PubMed ID: 12118200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Glimepiride].
    Nakamura N
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():351-6. PubMed ID: 12387017
    [No Abstract]   [Full Text] [Related]  

  • 12. [Sulfonylurea receptors and their interaction with glimepiride].
    Zueva NA; Sologub NV; Efimov AS
    Lik Sprava; 2003; (2):35-9. PubMed ID: 12774471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics.
    Tayek J
    Diabetes Obes Metab; 2008 Nov; 10(11):1128-9; author reply 1129-30. PubMed ID: 18671799
    [No Abstract]   [Full Text] [Related]  

  • 14. Sulfonylurea use before stroke does not influence outcome.
    Favilla CG; Mullen MT; Ali M; Higgins P; Kasner SE;
    Stroke; 2011 Mar; 42(3):710-5. PubMed ID: 21330623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas.
    Sato R; Watanabe H; Genma R; Takeuchi M; Maekawa M; Nakamura H
    Pharmacogenomics; 2010 Dec; 11(12):1743-50. PubMed ID: 21142918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration.
    Engler RL; Yellon DM
    Circulation; 1996 Nov; 94(9):2297-301. PubMed ID: 8901685
    [No Abstract]   [Full Text] [Related]  

  • 17. Glibenclamide improves neurological function in neonatal hypoxia-ischemia in rats.
    Zhou Y; Fathali N; Lekic T; Tang J; Zhang JH
    Brain Res; 2009 May; 1270():131-9. PubMed ID: 19306849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
    Horsdal HT; Mehnert F; Rungby J; Johnsen SP
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):717-25. PubMed ID: 21536457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfonylurea Pretreatment and In-Hospital Use Does Not Impact Acute Ischemic Strokes (AIS) Outcomes Following Intravenous Thrombolysis.
    Tsivgoulis G; Goyal N; Iftikhar S; Zand R; Chang JJ; Elijovich L; Alexandrov AW; Malkoff MD; Alexandrov AV
    J Stroke Cerebrovasc Dis; 2017 Apr; 26(4):795-800. PubMed ID: 27865697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ATP-sensitive potassium channel--sulfonylurea receptor].
    Yamada Y; Sunaga Y
    Nihon Rinsho; 1997 Oct; 55 Suppl():458-62. PubMed ID: 9392149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.